Trial · NCT01392183
Participant flow22
How many started, completed or left each group, period by period.
1 to 20 of 22
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Drug Administration | STARTED | Temsirolimus (Control Group) | 35 | |
| First Drug Administration | STARTED | Pazopanib (Treatment Group) | 34 | |
| First Drug Administration | Eligible to Cross Over to 2nd Drug | Temsirolimus (Control Group) | 29 | |
| First Drug Administration | Eligible to Cross Over to 2nd Drug | Pazopanib (Treatment Group) | 31 | |
| First Drug Administration | COMPLETED | Temsirolimus (Control Group) | 21 | |
| First Drug Administration | COMPLETED | Pazopanib (Treatment Group) | 15 | |
| First Drug Administration | NOT COMPLETED | Temsirolimus (Control Group) | 14 | |
| First Drug Administration | NOT COMPLETED | Pazopanib (Treatment Group) | 19 | |
| Second Drug Administration | STARTED | Temsirolimus (Control Group) | 21 | |
| Second Drug Administration | STARTED | Pazopanib (Treatment Group) | 15 | |
| Second Drug Administration | Treatment Ended: Progression | Temsirolimus (Control Group) | 18 | |
| Second Drug Administration | Treatment Ended: Progression | Pazopanib (Treatment Group) | 11 | |
| Second Drug Administration | Treatment Ended: Adverse Events | Temsirolimus (Control Group) | 1 | |
| Second Drug Administration | Treatment Ended: Adverse Events | Pazopanib (Treatment Group) | 2 | |
| Second Drug Administration | Treatment Ended: Participant Withdrew | Temsirolimus (Control Group) | 2 | |
| Second Drug Administration | Treatment Ended: Participant Withdrew | Pazopanib (Treatment Group) | 1 | |
| Second Drug Administration | Treatment Ended: Death | Temsirolimus (Control Group) | 0 | |
| Second Drug Administration | Treatment Ended: Death | Pazopanib (Treatment Group) | 1 | |
| Second Drug Administration | COMPLETED | Temsirolimus (Control Group) | 21 | |
| Second Drug Administration | COMPLETED | Pazopanib (Treatment Group) | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01392183/flow